In this article we will discuss Olaparib (Description-14). So, let’s get started.
Carcinogenicity studies have not been conducted with Olaparib.
Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian (CHO) cells and in an in vivo rat bone marrow micronucleus assay.
This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of Olaparib and indicates potential for genotoxicity in humans.
Olaparib was not
mutagenic in a bacterial reverse mutation (Ames) test.